

Peter G Kerr

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3917779/publications.pdf>

Version: 2024-02-01

232
papers

12,800
citations

25014

57
h-index

28275

105
g-index

232
all docs

232
docs citations

232
times ranked

11878
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. <i>Journal of Vascular Access</i> , 2024, 25, 193-202.	0.5	2
2	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1472-1481.	0.4	1
3	Dietary habits in Australian, New Zealand and Malaysian patients with end stage kidney failure: A pre-specified cross-sectional study of the FAVOURED trial participants. <i>Journal of Human Nutrition and Dietetics</i> , 2022, 35, 1178-1191.	1.3	0
4	Taking a broader view of the health care needs of people with chronic kidney disease. <i>Medical Journal of Australia</i> , 2022, 216, 137-138.	0.8	1
5	CKD—Where Have All the Women Gone?. <i>Kidney International Reports</i> , 2022, 7, 375-377.	0.4	1
6	A pilot study comparing the efficiency of a novel asymmetric cellulose triacetate (<sc>ATA</sc>) dialyser membrane (<sc>Solaceaâ€”190H</sc>) to a standard high flux polysulfone dialyser membrane (<sc>FX</sc>â€”80) in the setting of extended hours haemodialysis. <i>Nephrology</i> , 2022, 27, 494-500.	0.7	3
7	A Novel Approach to Enhance the Regenerative Potential of Circulating Endothelial Progenitor Cells in Patients with End-Stage Kidney Disease. <i>Biomedicines</i> , 2022, 10, 883.	1.4	2
8	The impact of the Christmas holiday effect on interdialytic weight gain in hemodialysis patients: A multicenter observational retrospective cohort study. <i>Hemodialysis International</i> , 2021, 25, 257-264.	0.4	0
9	Home and facility haemodialysis patients: a comparison of outcomes in a matched cohort. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1070-1077.	0.4	2
10	Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics. <i>Kidney International Reports</i> , 2021, 6, 272-283.	0.4	28
11	Clinical impact of genomic testing in patients with suspected monogenic kidney disease. <i>Genetics in Medicine</i> , 2021, 23, 183-191.	1.1	70
12	<i>Nephrology in Australia.</i> , 2021, , 701-721.		0
13	Peritoneal Dialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 315-325.	2.1	62
14	Hemodialysis Use and Practice Patterns: An International Survey Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 326-335.e1.	2.1	24
15	Kidney transplant recipient perspectives on telehealth during the COVIDâ€”19 pandemic. <i>Transplant International</i> , 2021, 34, 1517-1529.	0.8	16
16	Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. <i>Kidney International Reports</i> , 2021, 6, 2850-2861.	0.4	15
17	Relationship between measured and prescribed dialysate sodium in haemodialysis: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 695-703.	0.4	7
18	Availability, coverage, and scope of health information systems for kidney care across world countries and regions. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 159-167.	0.4	9

#	ARTICLE	IF	CITATIONS
19	Home based therapies: can wishes be realized?. Nephrology Dialysis Transplantation, 2020, 35, 1836-1839.	0.4	1
20	Predictors of Arteriovenous Fistula Failure: A Post Hoc Analysis of the FAVOURED Study. Kidney360, 2020, 1, 1259-1269.	0.9	8
21	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	3.0	52
22	Identifying Outcomes Important to Patients with Glomerular Disease and Their Caregivers. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 673-684.	2.2	66
23	Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. BMJ Open Diabetes Research and Care, 2020, 8, e000842.	1.2	11
24	Placental Pathology in Pregnancies After Kidney Transplantation. Transplantation, 2020, 104, e214-e215.	0.5	2
25	Smad4 promotes diabetic nephropathy by modulating glycolysis and <scp>OXPHOS</scp>. EMBO Reports, 2020, 21, e48781.	2.0	39
26	Response to COVID-19 Infection in Hemodialysis Patients: An Australian Perspective. Kidney360, 2020, 1, 829-833.	0.9	1
27	The Use of Live Cell Imaging and Automated Image Analysis to Assist With Determining Optimal Parameters for Angiogenic Assay in vitro. Frontiers in Cell and Developmental Biology, 2019, 7, 45.	1.8	7
28	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. PLoS ONE, 2019, 14, e0219685.	1.1	11
29	Status of care for end stage kidney disease in countries and regions worldwide: international cross sectional survey. BMJ: British Medical Journal, 2019, 367, l5873.	2.4	131
30	Isolated proteinuria due to CUBN homozygous mutation "challenging the investigative paradigm. BMC Nephrology, 2019, 20, 330.	0.8	9
31	Identifying patient-important outcomes in polycystic kidney disease: An international nominal group technique study. Nephrology, 2019, 24, 1214-1224.	0.7	20
32	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in REnal Disease (FAVOURED) trial. PLoS ONE, 2019, 14, e0213274.	1.1	8
33	Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 37-47.	2.6	235
34	A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease. BMC Nephrology, 2019, 20, 113.	0.8	8
35	Risk factors for foot ulceration in adults with end-stage renal disease on dialysis: a prospective observational cohort study. BMC Nephrology, 2019, 20, 423.	0.8	11
36	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. Journal of Diabetes and Its Complications, 2019, 33, 63-68.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Renal genetics in Australia: Kidney medicine in the genomic age. <i>Nephrology</i> , 2019, 24, 279-286.	0.7	18
38	Biochemical comparison of 8 h haemodialysis and 4 h haemodiafiltration, and two dialysis membranes, in a randomized cross-over trial. <i>Nephrology</i> , 2019, 24, 542-549.	0.7	3
39	mTOR-mediated podocyte hypertrophy regulates glomerular integrity in mice and humans. <i>JCI Insight</i> , 2019, 4, .	2.3	69
40	Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2018, 72, 62-74.	2.1	39
41	Use of deferasirox (Exjade) for iron overload in peritoneal dialysis patients. <i>Nephrology</i> , 2018, 23, 887-889.	0.7	7
42	Global access of patients with kidney disease to health technologies and medications: findings from the Global Kidney Health Atlas project. <i>Kidney International Supplements</i> , 2018, 8, 64-73.	4.6	82
43	Global overview of health systems oversight and financing for kidney care. <i>Kidney International Supplements</i> , 2018, 8, 41-51.	4.6	41
44	Models of care for co-morbid diabetes and chronic kidney disease. <i>Nephrology</i> , 2018, 23, 711-717.	0.7	14
45	Endothelial Progenitor Cells and Vascular Health in Dialysis Patients. <i>Kidney International Reports</i> , 2018, 3, 205-211.	0.4	14
46	Preeclampsia and Long-term Renal Function in Women Who Underwent Kidney Transplantation. <i>Obstetrics and Gynecology</i> , 2018, 131, 57-62.	1.2	26
47	An Interview Study of Patient and Caregiver Perspectives on Advance Care Planning in ESRD. <i>American Journal of Kidney Diseases</i> , 2018, 71, 216-224.	2.1	46
48	The stability and variability of serum and plasma fibroblast growth factor-23 levels in a haemodialysis cohort. <i>BMC Nephrology</i> , 2018, 19, 325.	0.8	11
49	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 215.	1.0	5
50	Aortic vascular calcification is inversely associated with the trabecular bone score in patients receiving dialysis. <i>Bone</i> , 2018, 113, 118-123.	1.4	20
51	Nephrology in the Oceania-South East Asia region: perspectives and challenges. <i>Kidney International</i> , 2018, 94, 465-470.	2.6	7
52	Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 84.	2.5	51
53	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access Outcomes in RENal Disease (FAVOURED) study. <i>Nephrology</i> , 2017, 22, 823-824.	0.7	3
54	The effect of holiday haemodialysis treatments on patient mood, adverse symptoms and subjective wellbeing using the Big Red Kidney Bus. <i>Nephrology</i> , 2017, 22, 107-113.	0.7	6

#	ARTICLE	IF	CITATIONS
55	Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey. <i>American Journal of Kidney Diseases</i> , 2017, 70, 464-475.	2.1	218
56	Serum phosphorus levels and fracture following renal transplantation. <i>Clinical Endocrinology</i> , 2017, 87, 141-148.	1.2	13
57	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. <i>JAMA Internal Medicine</i> , 2017, 177, 184.	2.6	77
58	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e017695.	0.8	38
59	Urolithiasis is prevalent and associated with reduced bone mineral density in β -thalassaemia major. <i>Internal Medicine Journal</i> , 2017, 47, 1064-1067.	0.5	10
60	Home Hemodialysis: What Is Old Is New Again. <i>Contributions To Nephrology</i> , 2017, 190, 146-155.	1.1	8
61	The fragility of significant results underscores the need of larger randomized controlled trials in nephrology. <i>Kidney International</i> , 2017, 92, 1469-1475.	2.6	47
62	Haemolysis in haemodialysis. <i>Nephrology</i> , 2017, 22, 838-847.	0.7	28
63	The association between patient activation and self-care practices: A cross-sectional study of an Australian population with comorbid diabetes and chronic kidney disease. <i>Health Expectations</i> , 2017, 20, 1375-1384.	1.1	51
64	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 427-432.	1.2	24
65	Low versus high dialysate calcium concentration in alternate night nocturnal hemodialysis: A randomized controlled trial. <i>Hemodialysis International</i> , 2017, 21, 19-28.	0.4	6
66	Factors associated with foot ulceration and amputation in adults on dialysis: a cross-sectional observational study. <i>BMC Nephrology</i> , 2017, 18, 293.	0.8	38
67	Standardised Outcomes in Nephrology Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease. <i>Trials</i> , 2017, 18, 560.	0.7	20
68	Preventing Intradialytic Hypotension: Translating Evidence into Practice. <i>Nephrology Nursing Journal</i> , 2017, 44, 131-151.	0.1	4
69	Primary and tertiary health professionals' views on the health-care of patients with co-morbid diabetes and chronic kidney disease – a qualitative study. <i>BMC Nephrology</i> , 2016, 17, 50.	0.8	17
70	Different faces of <i>Nocardia</i> infection in renal transplant recipients. <i>Nephrology</i> , 2016, 21, 254-260.	0.7	8
71	Baseline characteristics of the omega-3 fatty acids (fish oils) and aspirin in vascular access outcomes in renal disease (FAVOURER) study. <i>Nephrology</i> , 2016, 21, 217-228.	0.7	10
72	Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices. <i>Lancet</i> , The, 2016, 388, 294-306.	6.3	295

#	ARTICLE	IF	CITATIONS
73	Human podocyte depletion in association with older age and hypertension. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, F656-F668.	1.3	55
74	Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. <i>EBioMedicine</i> , 2016, 12, 263-269.	2.7	95
75	Reliability and validity of the coping strategy inventory-short form applied to hemodialysis patients in 13 countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>Journal of Psychosomatic Research</i> , 2016, 91, 12-19.	1.2	17
76	Conservative Management and End-of-Life Care in an Australian Cohort with ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2195-2203.	2.2	54
77	Keeping Home Dialysis Patients at Home. <i>American Journal of Kidney Diseases</i> , 2016, 67, 542-544.	2.1	4
78	How much is enough? An investigation of the relationship between haemodialysis adequacy and quality of life of elderly patients. <i>Nephrology</i> , 2016, 21, 314-320.	0.7	3
79	Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. <i>Bone</i> , 2016, 85, 55-58.	1.4	25
80	Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. <i>American Journal of Kidney Diseases</i> , 2016, 67, 617-628.	2.1	42
81	Patient and Caregiver Priorities for Outcomes in Hemodialysis: An International Nominal Group Technique Study. <i>American Journal of Kidney Diseases</i> , 2016, 68, 444-454.	2.1	232
82	Human mesenchymal stem cells alter the gene profile of monocytes from patients with Type 2 diabetes and end-stage renal disease. <i>Regenerative Medicine</i> , 2016, 11, 145-158.	0.8	13
83	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. <i>PLoS ONE</i> , 2016, 11, e0146615.	1.1	40
84	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0168491.	1.1	33
85	Renal allograft re-use and herpetic re-infection. <i>Nephrology</i> , 2015, 20, 17-21.	0.7	7
86	Standardised outcomes in nephrology – Haemodialysis (SONG-HD): study protocol for establishing a core outcome set in haemodialysis. <i>Trials</i> , 2015, 16, 364.	0.7	67
87	Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. <i>Kidney International</i> , 2015, 88, 1030-1046.	2.6	127
88	Research Priorities in CKD: Report of a National Workshop Conducted in Australia. <i>American Journal of Kidney Diseases</i> , 2015, 66, 212-222.	2.1	73
89	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in Renal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. <i>BMC Nephrology</i> , 2015, 16, 89.	0.8	21
90	Temporal Changes in Mortality Risk by Dialysis Modality in the Australian and New Zealand Dialysis Population. <i>American Journal of Kidney Diseases</i> , 2015, 66, 489-498.	2.1	41

#	ARTICLE	IF	CITATIONS
91	Podocyte Number in Children and Adults. Journal of the American Society of Nephrology: JASN, 2015, 26, 2277-2288.	3.0	61
92	<scp>DEBATE</scp>: Should Dialysis at Home be Mandatory for All Suitable <scp>ESRD</scp> Patients?. Seminars in Dialysis, 2015, 28, 147-154.	0.7	7
93	Vitamin D therapy in chronic kidney disease: back to the future?. Clinical Nephrology, 2015, 84 (2015), 65-74.	0.4	5
94	A pilot study of an influenza vaccination or mask mandate in an Australian tertiary health service. Medical Journal of Australia, 2014, 200, 83-84.	0.8	10
95	The Authors Reply. Kidney International, 2014, 86, 649.	2.6	1
96	Glomerular hypertrophy in subjects with low nephron number: contributions of sex, body size and race. Nephrology Dialysis Transplantation, 2014, 29, 1686-1695.	0.4	23
97	High rates of death and hospitalization follow bone fracture among hemodialysis patients. Kidney International, 2014, 85, 166-173.	2.6	276
98	Increasing home dialysis knowledge through a web-based e-learning program. Nephrology, 2014, 19, 345-351.	0.7	9
99	What are the Causes of the Ill Effects of Chronic Hemodialysis?. Seminars in Dialysis, 2014, 27, 18-21.	0.7	1
100	Thalassemia Bone Disease: A 19-Year Longitudinal Analysis. Journal of Bone and Mineral Research, 2014, 29, 2468-2473.	3.1	50
101	Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. Diabetes Research and Clinical Practice, 2014, 104, 84-91.	1.1	24
102	Histopathologic and Clinical Predictors of Kidney Outcomes in ANCA-Associated Vasculitis. American Journal of Kidney Diseases, 2014, 63, 227-235.	2.1	80
103	Blood Pressure and Blood Volume: Acute and Chronic Considerations in Hemodialysis. Seminars in Dialysis, 2013, 26, 62-72.	0.7	11
104	Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 2013, 61, 247-253.	2.1	52
105	Vancomycin-resistant enterococci colonization does not increase mortality in end-stage kidney failure: a case-control study. Journal of Hospital Infection, 2013, 85, 289-296.	1.4	6
106	Serum 25-Hydroxyvitamin D Deficiency and the 5-Year Incidence of CKD. American Journal of Kidney Diseases, 2013, 62, 58-66.	2.1	45
107	Thrice-weekly nocturnal hemodialysis: the overlooked alternative to improve patient outcomes. Nephrology Dialysis Transplantation, 2013, 28, 2447-2455.	0.4	15
108	<scp>KHA&CARI</scp> guideline: Dialysis adequacy (haemodialysis): Dialysis membranes. Nephrology, 2013, 18, 485-488.	0.7	17

#	ARTICLE	IF	CITATIONS
109	Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4180-4188.	0.4	144
110	Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. <i>Kidney International</i> , 2012, 82, 212-219.	2.6	60
111	Dialysis in Australia and New Zealand. , 2012, , 611-619.		1
112	Blood pressure levels and mortality risk among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. <i>Kidney International</i> , 2012, 82, 570-580.	2.6	120
113	Water quality in conventional and home haemodialysis. <i>Nature Reviews Nephrology</i> , 2012, 8, 725-734.	4.1	19
114	25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and) Tj ETQq0 0.0 rgBT /Overlock 10	0.8	33
115	The Directed Differentiation of Human iPS Cells into Kidney Podocytes. <i>PLoS ONE</i> , 2012, 7, e46453.	1.1	163
116	Phosphate Binder Use and Mortality Among Hemodialysis Patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Evaluation of Possible Confounding by Nutritional Status. <i>American Journal of Kidney Diseases</i> , 2012, 60, 90-101.	2.1	159
117	A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 219-222.	3.1	21
118	Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. <i>Clinical Nephrology</i> , 2011, 76, 233-243.	0.4	19
119	How Australian nephrologists view home dialysis: Results of a national survey. <i>Nephrology</i> , 2011, 16, 446-452.	0.7	62
120	Attenuation of aortic calcification with lanthanum carbonate <i>versus</i> calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. <i>Nephrology</i> , 2011, 16, 290-298.	0.7	109
121	Increasing home based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. <i>Nephrology</i> , 2011, 16, 53-56.	0.7	20
122	Lateral lumbar X-ray assessment of abdominal aortic calcification in Australian haemodialysis patients. <i>Nephrology</i> , 2011, 16, 389-395.	0.7	25
123	Effect of exercise on albuminuria in people with diabetes. <i>Nephrology</i> , 2011, 16, 704-709.	0.7	13
124	Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial. <i>Internal Medicine Journal</i> , 2011, 41, 825-832.	0.5	4
125	Home Hemodialysis in Australia and New Zealand: How and Why it has been Successful. <i>Seminars in Dialysis</i> , 2011, 24, 658-663.	0.7	21
126	Alternate Night Nocturnal Hemodialysis: The Australian Experience. <i>Seminars in Dialysis</i> , 2011, 24, 664-667.	0.7	13

#	ARTICLE	IF	CITATIONS
127	Water-soluble vitamin levels in extended hours hemodialysis. <i>Hemodialysis International</i> , 2011, 15, 30-38.	0.4	37
128	Increasing home-based dialysis therapies to tackle dialysis burden around the world: A position statement on dialysis economics from the 2nd Congress of the International Society for Hemodialysis. <i>Hemodialysis International</i> , 2011, 15, 10-14.	0.4	11
129	International Differences in Hemodialysis Delivery and Their Influence on Outcomes. <i>American Journal of Kidney Diseases</i> , 2011, 58, 461-470.	2.1	10
130	Home Hemodialysis and Mortality Risk in Australian and New Zealand Populations. <i>American Journal of Kidney Diseases</i> , 2011, 58, 782-793.	2.1	168
131	Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). <i>Pediatric Nephrology</i> , 2011, 26, 1753-1757.	0.9	127
132	Longitudinal Body Composition Changes Due to Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1668-1675.	2.2	47
133	Generation of Induced Pluripotent Stem Cells from Human Kidney Mesangial Cells. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1213-1220.	3.0	83
134	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. <i>American Journal of Nephrology</i> , 2011, 34, 226-232.	1.4	22
135	The ultrafiltration coefficient of a dialyser (KUF) is not a fixed value, and it follows a parabolic function: the new concept of KUF max. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 636-640.	0.4	22
136	Improving CKD-MBD management in haemodialysis patients: barrier analysis for implementing better practice. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1319-1326.	0.4	39
137	Nocturnal hemodialysis "should we still provide this therapy?. <i>Nature Reviews Nephrology</i> , 2011, 7, 611-612.	4.1	2
138	Transition from pediatric to adult renal services: a consensus statement by the International Society of Nephrology (ISN) and the International Pediatric Nephrology Association (IPNA). <i>Kidney International</i> , 2011, 80, 704-707.	2.6	112
139	Prospective Quality-of-Life Monitoring of Simultaneous Pancreas and Kidney Transplant Recipients Using the 36-Item Short Form Health Survey. <i>American Journal of Kidney Diseases</i> , 2010, 55, 698-707.	2.1	41
140	Effect of Alendronate on Vascular Calcification in CKD Stages 3 and 4: A Pilot Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2010, 56, 57-68.	2.1	99
141	A Rational Guide to Reducing Fracture Risk in Dialysis Patients. <i>Seminars in Dialysis</i> , 2010, 23, 43-54.	0.7	16
142	Using vertebral bone densitometry to determine aortic calcification in patients with chronic kidney disease. <i>Nephrology</i> , 2010, 15, 575-583.	0.7	12
143	Review: Membranes for haemodialysis. <i>Nephrology</i> , 2010, 15, 381-385.	0.7	40
144	Home haemodialysis in Australia " is the wheel turning full circle?. <i>Medical Journal of Australia</i> , 2010, 192, 403-406.	0.8	22

#	ARTICLE	IF	CITATIONS
145	Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 920-926.	0.4	13
146	Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 4009-4017.	0.4	73
147	Body composition in home haemodialysis versus conventional haemodialysis: a cross-sectional, matched, comparative study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 568-573.	0.4	8
148	Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. <i>Kidney International</i> , 2010, 77, 1098-1106.	2.6	357
149	Determination and Validation of Aortic Calcification Measurement from Lateral Bone Densitometry in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 119-127.	2.2	38
150	Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 221-233.	2.2	117
151	Effect of a Vascular Access Nurse Coordinator to Reduce Central Venous Catheter Use in Incident Hemodialysis Patients: A Quality Improvement Report. <i>American Journal of Kidney Diseases</i> , 2009, 53, 99-106.	2.1	71
152	Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access Outcomes in RENal Disease (FAVOURED) study. <i>BMC Nephrology</i> , 2009, 10, 1.	0.8	58
153	Relationship between vascular calcification, arterial stiffness and bone mineral density in a cross-sectional study of prevalent Australian haemodialysis patients. <i>Nephrology</i> , 2009, 14, 105-112.	0.7	35
154	A Single Low-Fixed Dose of Rituximab to Salvage Renal Transplants From Refractory Antibody-Mediated Rejection. <i>Transplantation</i> , 2009, 87, 286-289.	0.5	68
155	Hypercalcemia, Hypocalcemia, and Hypomagnesemia. , 2009, , 81-87.		0
156	Impact of intradialytic exercise on arterial compliance and B-type natriuretic peptide levels in hemodialysis patients. <i>Hemodialysis International</i> , 2008, 12, 254-263.	0.4	79
157	Home hemodialysis in Australia: Current perspective. <i>Hemodialysis International</i> , 2008, 12, S6-S10.	0.4	21
158	The impact of glycaemic control on outcomes in patients with end-stage renal disease and type 2 diabetes (Review Article). <i>Nephrology</i> , 2008, 13, 124-127.	0.7	10
159	Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients?. <i>Nephrology</i> , 2008, 13, 667-671.	0.7	20
160	Reduction in Î²2-Microglobulin With Super-flux Versus High-flux Dialysis Membranes: Results of a 6-Week, Randomized, Double-blind, Crossover Trial. <i>American Journal of Kidney Diseases</i> , 2008, 52, 93-101.	2.1	27
161	Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2008, 52, 519-530.	2.1	888
162	Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3654-3661.	0.4	68

#	ARTICLE	IF	CITATIONS
163	Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 23, 586-593.	0.4	214
164	ARTERIAL CALCIFICATION AND STIFFNESS IN CHRONIC KIDNEY DISEASE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 683-687.	0.9	21
165	Vascular calcification and arterial stiffness in chronic kidney disease: Implications and management. <i>Nephrology</i> , 2007, 12, 500-509.	0.7	71
166	Focal segmental glomerulosclerosis and Guillain-Barré syndrome associated with <i>Campylobacter</i> enteritis. <i>Internal Medicine Journal</i> , 2007, 37, 724-728.	0.5	9
167	The Impact of Standard High-Flux Polysulfone Versus Novel High-Flux Polysulfone Dialysis Membranes on Inflammatory Markers: A Randomized, Single-Blinded, Controlled Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2007, 49, 533-539.	2.1	22
168	Association of Carotid Intima-Medial Thickness and Indices of Arterial Stiffness With Cardiovascular Disease Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2007, 50, 622-630.	2.1	108
169	Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1108-1116.	1.2	208
170	Does monthly native arteriovenous fistula blood-flow surveillance detect significant stenosis? a randomized controlled trial. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 2498-2506.	0.4	74
171	Renal anaemia: Recent developments, innovative approaches and future directions for improved management (Review Article). <i>Nephrology</i> , 2006, 11, 542-548.	0.7	12
172	Review of dialysate calcium concentration in hemodialysis. <i>Hemodialysis International</i> , 2006, 10, 326-337.	0.4	60
173	Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients. <i>Kidney International</i> , 2006, 69, 1229-1236.	2.6	124
174	Anti-CD20 antibody treatment in refractory Class IV lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 291-293.	0.4	8
175	Measurement of vascular calcification using CT fistulograms. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 484-490.	0.4	14
176	Prevalence and treatment of cardiovascular disease and traditional risk factors in Australian adults with renal insufficiency. <i>Nephrology</i> , 2005, 10, 40-47.	0.7	15
177	Renal dialysis abatement: lessons from a social study. <i>Palliative Medicine</i> , 2005, 19, 389-396.	1.3	91
178	Effects of Early and Late Intervention with Epoetin A on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 148-156.	3.0	206
179	Vascular Access and All-Cause Mortality: A Propensity Score Analysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 477-486.	3.0	384
180	Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results. <i>Nephrology</i> , 2004, 9, 130-141.	0.7	37

#	ARTICLE	IF	CITATIONS
181	Determinants of native arteriovenous fistula blood flow. <i>Nephrology</i> , 2004, 9, 205-211.	0.7	14
182	Seasonal modifications in blood pressure are mainly related to interdialytic body weight gain in dialysis patients. <i>Kidney International</i> , 2004, 65, 1795-1801.	2.6	40
183	Arterial function after successful renal transplantation. <i>Kidney International</i> , 2004, 65, 1882-1889.	2.6	95
184	Time and exercise improve phosphate removal in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2004, 43, 85-89.	2.1	110
185	Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. <i>American Journal of Kidney Diseases</i> , 2004, 43, 197-208.	2.1	161
186	Vascular access practice patterns in the New Zealand hemodialysis population. <i>American Journal of Kidney Diseases</i> , 2004, 43, 696-704.	2.1	23
187	Anemia management and outcomes from 12 countries in the dialysis outcomes and practice patterns study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2004, 44, 94-111.	2.1	600
188	Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2004, 44, 34-38.	2.1	133
189	Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>American Journal of Kidney Diseases</i> , 2004, 44, 34-38.	2.1	269
190	Prospective Psychosocial Monitoring of Living Kidney Donors Using the Short Form-36 Health Survey: Results at 12 Months. <i>Transplantation</i> , 2004, 78, 1384-1389.	0.5	82
191	Treatment for lupus nephritis. , 2004, , CD002922.		50
192	Native arteriovenous fistula blood flow and resistance during hemodialysis. <i>American Journal of Kidney Diseases</i> , 2003, 41, 132-139.	2.1	27
193	Health-related quality of life in Australian adults with renal insufficiency: A population-based study. <i>American Journal of Kidney Diseases</i> , 2003, 41, 596-604.	2.1	78
194	Evaluation of fistula blood flow and resistance by regression analysis: in reply. <i>American Journal of Kidney Diseases</i> , 2003, 42, 614a-615.	2.1	0
195	Epidemiology of vascular access in the Australian hemodialysis population. <i>Kidney International</i> , 2003, 64, 1893-1902.	2.6	27
196	Cardiovascular risk in dialysis patients: A comparison of risk factors and cardioprotective therapy between 1996 and 2001. <i>Nephrology</i> , 2003, 8, 177-183.	0.7	19
197	Historical controlled trial of OKT3 versus basiliximab induction therapy in simultaneous pancreas-renal transplantation. <i>Nephrology</i> , 2003, 8, 212-216.	0.7	11
198	Randomized, placebo-controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients. <i>Internal Medicine Journal</i> , 2003, 33, 489-494.	0.5	11

#	ARTICLE	IF	CITATIONS
199	Prevalence of Kidney Damage in Australian Adults: The AusDiab Kidney Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, S131-S138.	3.0	574
200	Prospective psychosocial monitoring of living kidney donors using the SF-36 health survey. <i>Transplantation</i> , 2003, 76, 807-809.	0.5	40
201	Karyomegalic nephropathy: an uncommon cause of progressive renal failure. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1914-1920.	0.4	34
202	ESRD in Australia and New Zealand at the end of the millennium: A report from the ANZDATA registry. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1122-1131.	2.1	63
203	Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. <i>Kidney International</i> , 2002, 62, 2167-2175.	2.6	157
204	High-flux dialysers*. <i>Nephrology</i> , 2002, 7, 33-36.	0.7	0
205	Predicting vascular access failure: A collective review. <i>Nephrology</i> , 2002, 7, 170-176.	0.7	3
206	Increased incidence of benign breast disease in female renal transplant patients receiving cyclosporin. <i>ANZ Journal of Surgery</i> , 2002, 72, 222-225.	0.3	22
207	Comparison of dialysis adequacy at two dialysate potassium concentrations. <i>Nephrology</i> , 2001, 6, 89-91.	0.7	2
208	Is there a role for plasma exchange in rapidly progressive glomerulonephritis?. <i>Nephrology</i> , 2001, 6, 141-143.	0.7	5
209	Carotid Artery Intima-Medial Thickness Is Increased In Chronic Renal Failure. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 639-641.	0.9	39
210	Outcome of a screening program for vancomycin-resistant enterococci in a hospital in Victoria. <i>Medical Journal of Australia</i> , 1999, 171, 133-136.	0.8	40
211	Dialyzer Performance in the Clinic: Comparison of Six Low-Flux Membranes. <i>Artificial Organs</i> , 1999, 23, 817-821.	1.0	16
212	Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement. <i>Kidney International</i> , 1997, 52, 530-537.	2.6	56
213	Dialyzer Reuse: Interaction Between Dialyzer Membrane, Disinfectant (Formalin), and Blood During Dialyzer Reprocessing. <i>Artificial Organs</i> , 1996, 20, 53-55.	1.0	7
214	Assessment of the Nutritional State of Dialysis Patients. <i>Blood Purification</i> , 1996, 14, 382-387.	0.9	43
215	Evaluation of an in-line dialysate urea monitor including assessment of 'V'. <i>Nephrology</i> , 1996, 2, 195-198.	0.7	0
216	Phosphate removal in haemodialysis: Effect of two different dialysis membranes. <i>Nephrology</i> , 1996, 2, 405-407.	0.7	0

#	ARTICLE	IF	CITATIONS
217	Kt/V in CAPD by different estimations of V. <i>Kidney International</i> , 1995, 48, 563-569.	2.6	47
218	Recent trends in haemodialysis: Australia 1994. <i>Nephrology</i> , 1995, 1, 3-10.	0.7	1
219	Cells surrounding haemodialysis-associated amyloid deposits are mainly macrophages. <i>Nephrology Dialysis Transplantation</i> , 1994, 9, 662-667.	0.4	55
220	The Adequacy of Fragmin as a Single Bolus Dose with Reused Dialyzers. <i>Artificial Organs</i> , 1994, 18, 416-419.	1.0	12
221	DEOXYSPERGUALIN SUPPRESSES LOCAL MACROPHAGE PROLIFERATION IN RAT RENAL ALLOGRAFT REJECTION. <i>Transplantation</i> , 1994, 58, 596-601.	0.5	58
222	Control of post-transplant erythrocytosis by enalapril. <i>Medical Journal of Australia</i> , 1994, 161, 544-546.	0.8	3
223	Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. <i>Kidney International</i> , 1993, 43, 630-640.	2.6	108
224	Whole Blood Serotonin Levels Are Markedly Elevated in Patients on Dialytic Therapy. <i>American Journal of Nephrology</i> , 1992, 12, 14-18.	1.4	32
225	The Effects of Reprocessing High-Flux Polysulfone Dialyzers With Peroxyacetic Acid on β_2 -Microglobulin Removal in Hemodiafiltration. <i>American Journal of Kidney Diseases</i> , 1992, 19, 433-438.	2.1	26
226	Failure of a daily haemofiltration programme using a highly permeable membrane to return β_2 -microglobulin concentrations to normal in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 1992, 7, 924-930.	0.4	58
227	Bilateral Periureteric Junction Obstruction Causing Renal Failure in Two Elderly Patients. <i>American Journal of Nephrology</i> , 1989, 9, 47-50.	1.4	4
228	THE EFFECTS OF OKT3 THERAPY ON INFILTRATING LYMPHOCYTES IN REJECTING RENAL ALLOGRAFTS. <i>Transplantation</i> , 1989, 48, 33-36.	0.5	23
229	PHENOTYPIC DEFINITION OF PRIMED T CELLS IN HUMAN RENAL ALLOGRAFTS. <i>Transplantation</i> , 1989, 48, 787-789.	0.5	9
230	of Intermittent v Continuous Therapy. <i>American Journal of Kidney Diseases</i> , 1988, 12, 304-306.	2.1	42
231	Zygomycosis requiring amputation of the hand: an isolated case in a patient receiving haemodialysis. <i>Medical Journal of Australia</i> , 1988, 148, 258-259.	0.8	35
232	HEMODYNAMIC AND PLASMA RENIN RESPONSES TO TREATMENT OF A RENAL ARTERIOVENOUS MALFORMATION. <i>Australian and New Zealand Journal of Medicine</i> , 1986, 16, 1-4.	0.5	3